Ocuphire Pharma Investor Day Presentation Deck slide image

Ocuphire Pharma Investor Day Presentation Deck

P 103 Presbyopia Market Segments Tens of Millions of Likely Early Users → Emmetropes, Hyperopes, and Pseudophakes ~128M Presbyopes in the US ● NORMAL VISION Emmetropes Naturally occurring clear vision • No refractive error/post-LASIK 66 M HYPEROPIA Hyperopes Poor near vision (starting at age 40) 14 M PSUEDOPHAKIA Pseudophakes • Cataract surgery for artificial lens (monofocal, multifocal IOLS) 9 M Assume 50% use eye drops* ~44 M Patients Likely To Be Early Users of Presbyopia Eyedrops Global Prevalence of Presbyopia, 2018, Fortune Business Insights Reading Glasses Forecast 2016-2027, NEI 2010 data. *GlobalData Market Research 2020 Vitale S. et. Al. JAMA Ophthalmology, 2008, Vision problems, US, Arch. Ophthal, 2014, Vision Monday. MYOPIA Myopes Poor distance vision 39 M Ocuphire PHARMA
View entire presentation